• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Secondary-progressive multiple sclerosis (SPMS)

July 20, 2021
Recommend to a Colleague print
 

Provides information on SPMS diagnosis, active and progressive sub-phenotypes, time to SPMS in historical and contemporary cohorts, age and EDSS score as predictors of SPMS, and patients’ symptom that may herald the transition to SPMS.

10 slides

Download slide deck

TOPICS: Library, MS
Recommend to a Colleague

Related Posts

  • High-efficacy DMTs for MS: the year in review
    December 1, 2025
  • Ocrelizumab use throughout the MS clinical course: highlights from ECTRIMS 2025
    October 15, 2025
  • Early use and long-term safety of ofatumumab: highlights from ECTRIMS 2025
    October 7, 2025
  • ECTRIMS 2025 HIGHLIGHTS – SATURDAY, SEPTEMBER 27, 2025
    September 27, 2025
  • ECTRIMS 2025 HIGHLIGHTS – FRIDAY, SEPTEMBER 26, 2025
    September 26, 2025
Go back to home page

Browse by Topic

  • MS (427)
  • EPILEPSY (37)
  • ECTRIMS 2025 (7)
  • BIOMARKERS IN MS (60)
  • Library (18)
  • CLINICAL CASES IN MS (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • High-efficacy DMTs for MS: the year in review posted on December 1, 2025
  • CNS effects of Wegovy (semaglutide) posted on February 28, 2023
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions